Last updated: September 24, 2026
Oxsoralen-Ultra, a 10 mg methoxsalen capsule used with controlled UVA exposure, is a legacy photochemotherapy product with limited commercial scale. Its market is constrained by declining PUVA use, narrow indications, treatment-center requirements, and competition from newer psoriasis and vitiligo therapies. The product has no meaningful remaining exclusivity barrier based on its age and current regulatory profile. Bausch Health does not publicly disclose product-level revenue for Oxsoralen-Ultra, so its financial trajectory must be inferred from product status, category trends, and portfolio reporting.
What is Oxsoralen-Ultra and how is it used?
Oxsoralen-Ultra contains methoxsalen, a psoralen that increases skin sensitivity to UVA radiation. The capsule is administered before controlled UVA exposure in PUVA therapy.
The FDA-approved label identifies use in:
- Severe, disabling psoriasis that is not adequately responsive to other treatments.
- Vitiligo in conjunction with UVA exposure.
- Selected dermatologic conditions treated under specialist supervision.
The product is not a stand-alone oral dermatology therapy. Its use requires a UVA treatment system, trained clinical personnel, eye protection, dose escalation, and monitoring for phototoxicity and long-term skin complications. This delivery model limits prescription volume and makes treatment access dependent on specialized dermatology centers.
The main commercial product is Oxsoralen-Ultra 10 mg capsules. The active ingredient is methoxsalen, also known as 8-methoxypsoralen.
What is the FDA regulatory status of Oxsoralen-Ultra?
Oxsoralen-Ultra is an FDA-approved prescription drug associated with NDA 018601. The product has historically been marketed in the United States by Valeant Pharmaceuticals and later by Bausch Health-related entities. Its regulatory status is that of an established, mature small-molecule product rather than a newly developed or actively protected innovative medicine.
| Regulatory attribute |
Oxsoralen-Ultra position |
| Active ingredient |
Methoxsalen |
| Strength |
10 mg capsule |
| Drug class |
Psoralen |
| Administration |
Oral, before UVA exposure |
| Primary treatment model |
PUVA photochemotherapy |
| FDA pathway |
Approved NDA |
| NDA |
018601 |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Regulatory lifecycle |
Mature legacy product |
FDA labeling warns of severe phototoxic reactions, nausea, dizziness, headache, and the need for eye protection. Long-term PUVA exposure is associated with increased risk of nonmelanoma skin cancer, which affects physician and patient preferences even where methoxsalen remains clinically useful (U.S. Food and Drug Administration, n.d.-a).
What patents protect Oxsoralen-Ultra?
Oxsoralen-Ultra is not positioned as a product with meaningful remaining patent exclusivity. Methoxsalen and oral psoralen-based PUVA therapy have been used for decades, placing the original composition-of-matter and early method patents well beyond their ordinary U.S. patent terms.
Orange Book status
The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with approved drugs. A current Orange Book review should be used to confirm any residual listing tied to NDA 018601. Based on the product’s age and the absence of a recently developed formulation or delivery platform, Oxsoralen-Ultra is not expected to have a commercially material active patent estate (U.S. Food and Drug Administration, n.d.-b).
The relevant IP position can be summarized as follows:
| IP category |
Commercial assessment |
| Original methoxsalen composition patent |
Expired |
| Early PUVA method patents |
Expired |
| Oral capsule formulation patents |
Expected to be expired or nonmaterial |
| New delivery-system patents |
None identified as central to Oxsoralen-Ultra |
| Orange Book exclusivity |
No meaningful remaining exclusivity expected |
| Trade-secret exposure |
Limited to manufacturing, sourcing, and quality controls |
The absence of meaningful patent protection does not guarantee broad generic supply. Methoxsalen is a low-volume product, and commercial entry depends on expected demand, manufacturing economics, regulatory filing costs, and reliable access to active pharmaceutical ingredient.
When does Oxsoralen-Ultra lose exclusivity?
Oxsoralen-Ultra lost practical exclusivity many years ago. The product is not approaching a future loss-of-exclusivity event comparable to a modern specialty drug. Its commercial position is already post-exclusivity.
The relevant distinction is between legal exclusivity and practical market availability:
- Legal exclusivity: largely exhausted.
- Regulatory exclusivity: not a current commercial barrier.
- Generic substitution: possible in principle, but limited by market size and supply economics.
- Clinical substitution: increasingly available through non-PUVA therapies.
- Manufacturing scarcity: may remain a more important barrier than patents.
For a generic applicant, the likely pathway would be an abbreviated new drug application referencing the approved methoxsalen product, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. A Paragraph IV certification could be relevant only if an unexpired listed patent were present. No material Paragraph IV-driven challenge is a central feature of the product’s current market.
Are there Paragraph IV challenges to Oxsoralen-Ultra?
No major, publicly prominent Paragraph IV litigation campaign is associated with Oxsoralen-Ultra in the available commercial record. That outcome is consistent with the product’s small addressable market and old active ingredient.
A generic manufacturer evaluating the product would likely focus on:
- Whether a current reference-listed drug can support an ANDA.
- Whether an active Orange Book patent remains listed.
- Whether the product can be manufactured economically at low annual volume.
- Whether wholesalers and dermatology clinics will stock the product.
- Whether methoxsalen API supply is dependable.
The lack of visible Paragraph IV litigation suggests that the commercial opportunity has not justified an aggressive patent challenge. It does not indicate that generic entry is technically impossible.
What formulations are protected by Oxsoralen-Ultra patents?
The commercial product is an oral 10 mg capsule. No modern extended-release, transdermal, injectable, implantable, or device-linked formulation is central to the Oxsoralen-Ultra franchise.
The product’s differentiation historically came from the Ultra formulation and dosing characteristics rather than a durable technology platform. Any residual formulation value would be limited by:
- The age of the product.
- The availability of methoxsalen as an established active ingredient.
- The relatively simple oral dosage form.
- The absence of a large consumer or specialty-pharmacy franchise.
- The lack of a proprietary delivery device.
PUVA itself requires a UVA source, but that equipment is separate from the capsule product and does not create a durable Oxsoralen-Ultra patent moat.
How strong is the Oxsoralen-Ultra patent estate?
The patent estate is weak from a current commercial perspective.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Exhausted |
| Formulation differentiation |
Limited |
| Manufacturing exclusivity |
Potentially relevant but not publicly visible as a market barrier |
| Method-of-use protection |
Historical, not expected to block generic use |
| Device integration |
Not owned through the capsule product |
| Regulatory exclusivity |
Not material |
| Litigation leverage |
Low |
| Generic entry risk |
Moderate if a supplier sees adequate demand |
The principal risk is not a patent injunction. It is product discontinuation, supply interruption, or replacement by other dermatologic treatments.
What is the competitive landscape for Oxsoralen-Ultra?
Oxsoralen-Ultra competes within a shrinking PUVA segment and a much larger dermatology market.
Psoriasis competition
For psoriasis, PUVA competes with:
- Narrowband UVB phototherapy.
- Topical corticosteroids and vitamin D analogues.
- Retinoids.
- Methotrexate.
- Cyclosporine.
- Apremilast.
- Biologics targeting TNF, IL-17, IL-23, or IL-12/23 pathways.
- Oral targeted immunomodulators.
Biologics and oral targeted therapies have reduced the role of systemic photochemotherapy in many moderate-to-severe psoriasis patients. Their cost is materially higher, but their convenience, efficacy, and reduced dependence on treatment-center visits support continued displacement of PUVA.
Vitiligo competition
For vitiligo, PUVA has faced competition from:
- Narrowband UVB.
- Excimer laser.
- Topical corticosteroids.
- Topical calcineurin inhibitors.
- Topical ruxolitinib for eligible patients.
- Surgical and procedural approaches.
The approval of newer targeted treatments, including ruxolitinib cream for nonsegmental vitiligo, increases competitive pressure on older photochemotherapy approaches (Incyte Corporation, 2022).
Product comparison
| Product or treatment |
Commercial advantage over Oxsoralen-Ultra |
Limitation |
| Narrowband UVB |
No oral psoralen required; simpler safety profile |
Requires repeated clinic visits |
| Excimer laser |
Targeted treatment for localized disease |
Limited for extensive disease |
| Biologic psoriasis therapies |
High efficacy and home or office administration |
High cost and immunologic risks |
| Oral targeted psoriasis therapies |
Convenient administration |
Safety monitoring and systemic risks |
| Topical ruxolitinib |
Directly approved for eligible vitiligo patients |
Restricted indication and treatment duration considerations |
| Oxsoralen-Ultra plus UVA |
Established PUVA efficacy and low drug acquisition cost |
Phototoxicity, monitoring, clinic dependence, long-term cancer risk |
What is the financial trajectory of Oxsoralen-Ultra?
Public filings do not separately report Oxsoralen-Ultra revenue. Bausch Health reports results by business segment and selected products, but Oxsoralen-Ultra is not generally identified as a material standalone revenue contributor in public annual-report disclosures (Bausch Health Companies Inc., 2024).
The most supportable financial trajectory is:
- Mature revenue base with limited volume growth.
- Declining or stagnant demand as PUVA use contracts.
- Low pricing power because the active ingredient is old and patent protection is exhausted.
- Potential intermittent revenue uplift from supply shortages, but not a durable growth driver.
- High sensitivity to manufacturing and distribution costs because annual volume is likely modest.
- Limited strategic value unless the product supports a broader dermatology portfolio.
The product is unlikely to influence Bausch Health consolidated revenue, earnings, or valuation materially on a standalone basis. Its financial relevance is more likely to arise through portfolio completeness, physician relationships, and specialty-drug availability than through direct sales growth.
Revenue exposure assessment
| Financial factor |
Expected impact |
| U.S. prescription demand |
Low and structurally pressured |
| Price increases |
Possible but constrained by substitution and payer scrutiny |
| Generic competition |
Moderate risk, although entry may be unattractive |
| Manufacturing cost |
High relative importance |
| Wholesaler inventory |
Can create short-term volatility |
| International sales |
Potentially relevant but not publicly quantified |
| Contribution to Bausch Health |
Immaterial relative to major portfolio products |
| Long-term growth outlook |
Flat to declining |
What licensing deals affect Oxsoralen-Ultra?
No major recent licensing transaction has made Oxsoralen-Ultra a strategic growth asset. The product has historically moved within corporate dermatology portfolios rather than through a high-value external licensing structure.
Any commercial arrangement involving the product would likely concern:
- Distribution rights.
- Supply and manufacturing.
- Regional commercialization.
- Transfer of an established NDA.
- Dermatology portfolio restructuring.
The absence of a notable recent licensing transaction is consistent with the product’s low expected revenue and limited IP differentiation.
What manufacturing and supply barriers affect generic entry?
Manufacturing and supply conditions are more important than patent rights.
Methoxsalen capsules require compliance with FDA current good manufacturing practice standards, validated content uniformity, stability data, impurity controls, packaging controls, and a consistent API source. A manufacturer must also maintain a viable supply chain for a product with limited volume.
Potential barriers include:
- Low forecast demand.
- Minimum API purchase quantities.
- Limited qualified API suppliers.
- Low inventory turns.
- Specialized labeling and handling requirements.
- Commercial reluctance by wholesalers to carry slow-moving inventory.
- Difficulty achieving attractive margins after regulatory and quality costs.
These conditions can produce a market with no effective patent barrier but few active suppliers. That structure increases shortage risk without creating durable monopoly economics.
What generic launch scenarios exist for Oxsoralen-Ultra?
Three scenarios are commercially plausible.
Scenario 1: Continued branded or single-source supply
The incumbent maintains marketing authorization and supplies a small specialist market. Pricing can remain above commodity levels if reliable alternatives are absent, but total revenue remains limited.
Scenario 2: Low-cost generic entry
A generic manufacturer files an ANDA and enters with a lower price. The entrant gains share quickly if pharmacies and clinics substitute readily. The market may still remain small because PUVA utilization continues to decline.
Scenario 3: Product withdrawal or intermittent shortage
The incumbent exits because demand cannot support manufacturing and distribution costs. A replacement supplier may enter only after a shortage creates sufficient commercial visibility. Patients and clinics then move toward narrowband UVB, excimer therapy, or alternative drugs.
The third scenario is particularly relevant for legacy dermatology products. Commercial continuity depends more on supply economics than on IP enforcement.
What is the geographic coverage of Oxsoralen-Ultra?
The strongest commercial relevance is in the United States, where the product has an FDA-approved NDA and an established dermatology-use history. International availability varies by national registration, local suppliers, reimbursement, and the prevalence of PUVA treatment.
Geographic risks include:
- Different national approvals for methoxsalen products.
- Country-specific generic registration requirements.
- Local API and finished-dose manufacturing capacity.
- Reimbursement differences.
- Uneven availability of UVA treatment centers.
- Alternative use of narrowband UVB.
The United States is the most important jurisdiction for Orange Book and Paragraph IV analysis. European and other markets require separate national or regional regulatory review and cannot be assumed to mirror the U.S. patent or supply position.
What patent litigation and settlement agreements affect Oxsoralen-Ultra?
No material current patent litigation or high-profile settlement agreement is associated with Oxsoralen-Ultra in the available public record. The product’s litigation exposure is low because:
- The core active ingredient is old.
- The product is not a major revenue franchise.
- No active patent dispute is central to market access.
- Generic entry economics are limited.
- Commercial risk is concentrated in supply and substitution.
The absence of litigation should not be interpreted as evidence of strong market protection. It reflects the limited value of enforcing or challenging legacy rights.
Key Takeaways
- Oxsoralen-Ultra is an established 10 mg methoxsalen capsule used with UVA in PUVA therapy.
- Its commercial market is narrow and structurally pressured by declining PUVA use.
- The product has no expected material remaining composition, formulation, or method-of-use exclusivity.
- No prominent Paragraph IV challenge, patent litigation campaign, or settlement agreement defines the current market.
- Biosimilar risk is irrelevant because methoxsalen is a small-molecule drug, not a biologic.
- Generic entry is legally possible but may be commercially unattractive because of low demand and manufacturing economics.
- Bausch Health does not separately disclose Oxsoralen-Ultra revenue, making product-level financial modeling unavailable from public filings.
- The principal risks are supply interruption, product withdrawal, clinical substitution, and declining specialist use.
- The product is unlikely to have material impact on Bausch Health consolidated revenue or valuation.
FAQs About Oxsoralen-Ultra Market and Patent Risk
Is Oxsoralen-Ultra still FDA approved?
Oxsoralen-Ultra is associated with an FDA-approved NDA for methoxsalen 10 mg capsules used with UVA therapy. Current marketing and commercial availability should be distinguished from the underlying approval status.
Does Oxsoralen-Ultra have a biosimilar competitor?
No. Biosimilars apply to biologic products. Oxsoralen-Ultra is a small-molecule capsule, so any competitive product would generally be a generic methoxsalen product.
Can a generic manufacturer launch methoxsalen without infringing patents?
A generic manufacturer can potentially enter through an ANDA if no unexpired listed patent blocks approval and the applicant satisfies FDA requirements. The principal commercial challenge is likely market size and supply economics rather than patent infringement.
Why might Oxsoralen-Ultra remain expensive despite expired patents?
Low-volume manufacturing, limited API supply, inventory carrying costs, specialist distribution, and few competing suppliers can keep prices elevated after patent expiry.
Is Oxsoralen-Ultra a growth opportunity for pharmaceutical investors?
It is better characterized as a defensive or continuity product than a growth asset. Revenue upside is limited, while supply interruption, product discontinuation, and clinical substitution create the main investment risks.
References
Bausch Health Companies Inc. (2024). 2023 annual report. https://ir.bauschhealth.com/
Incyte Corporation. (2022). Opzelura (ruxolitinib) cream prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (n.d.-a). Oxsoralen-Ultra prescribing information. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
